Expert Interview
Discussing the potential of Povorcitinib, a JAK inhibitor in development by Incyte, for patients with Prurigo Nodularis (PN).
Ticker(s): INCYInstitution: Kaiser Permanente
- I treat roughly 100 patients with PN per year. I am familiar with the phase two study, this was just presented at the AAD conference in San Diego
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
